I just read the article that Clay linked to. I wonder what others think about it.
Personally (as one with some experience in reading research papers ableit in a different academic domain) I would ask further questions about their 'conclusions'.
For instance in their conclusions they say
because of increased awareness of the associ ated lifetime
risk of major thomboembolic and hemorrhagic complications,particularly stroke, that occur with mechanical valves despite optimal anticoagulation.
yet make no significant analysis of this aspect in their paper. I would get bollicked for that in an academic paper at my uni... But my training area is science and Medicine often seems to act more like Arts in their ways.
The statement:
By contrast, mechanical valve technology and antithrombotic treatment options have remained
relatively static.
would seem to ignore the points (found elsewhere) that other studies show that self monitoring and self testing (which I understood represents about 1% of warfarin patients in the USA) brings the data on thromboembolic events to quite equal to that of tissue valve recipients (who may in fact need to go on warfarin anyway
before a valve failure requiring reoperation due to the degeneration of the tissue valve).
A quote from the Mayo presentation:
a 77yo who had previously had a tissue valve replacement was presented in sever heart failure. It could be said that this was 'Gods hand' for 77 year olds. Its not true that tissue valves don't
thrombose, they do. If not identified it can be confused with heart failure. Patient is now anticoagulated
This patient would have died for lack of diagnosis of thromboembolism.
Also, from their conclusions:
Patients undergoing valve replacement with a mechanical valve can expect a linear annual risk of major hemorrhagic or embolic events, including stroke, of 2–4% per year for life compared with around 1% per year for bioprostheses
which given their light examination of the literature on anticoagulation I can only assume that would be assuming the 99% who are not on self care or self monitoring, which has been established (in other studies) to bring down the risks to within the bioprosthesis group. Again quoting from the meta-analysis review done by the Mayo
another study showing TIR for UC vs PSM showed
PSM was in range 78% and total related events dropped from 4.7% (UC) to 2.9% (PSM)
It showed also that PST reduced the bleed complications from 11% to 4.5% and Thromboembolic from 3.6% to 0.9%
UC = Usual Care
PSM = Patient Self Monitoring
PST = Patient Selft Testing
Those drops in complication rates suggest strongly otherwise than the conclusions in that paper. Given how few in the USA are doing PSM or PST I guess its easy to pull together modern data and present it as current when in fact the patients in the USA are not being treated in a modern way with respect to warfarin care.
I'm not going to do a full analysis on this, but to me it was just one more 'paper' with predominately a meta-analysis approach and confusing presentation of data. Probably done because in academic circles you have to get your publications count up as part of your KPI's. One of my fellow students had this on his door while writing up his PhD ...
Personally I've seen at least one academic who has such cut and paste approach to his papers that I have to print them and have them on the desk to see which is which. Remember its not plagiarism if you copy your own work!